公开(公告)号：US20110098481A1

公开(公告)日：2011-04-28

申请号：US12917935

申请日：2010-11-02

申请人： Takahiko MURATA ,  Masahiro AMAKAWA ,  Shin TERADAIRA ,  Yasushi MATSUMURA ,  Katsuhiko KONISHI

发明人： Takahiko MURATA ,  Masahiro AMAKAWA ,  Shin TERADAIRA ,  Yasushi MATSUMURA ,  Katsuhiko KONISHI

IPC分类号： C07D405/06

CPC分类号： C07D405/06 ,  A61K31/41

摘要： Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.

摘要翻译： 本发明提供由式（1）表示的化合物：其中，R 1和R 2各自独立地为氢原子或碳数为1-3的直链烷基，R 3为氢原子，具有碳数的烷基 1-4，烷氧基烷基，芳基，卤原子或卤代烷基，或其药学上可接受的盐，其与已知的PGI 2类似物不同，具有选择性EP4激动剂作用，和含有该化合物的药物，其中 可用于预防和/或治疗免疫疾病，消化道疾病，心血管疾病，心脏病，呼吸系统疾病，神经系统疾病，眼科疾病，肾病，肝病，骨病，皮肤疾病等。